The treatment of IBD ranges from mild to severe cases, employing agents such as anti-inflammatory drugs (e.g., 5-aminosalicylic acid [5-ASA] and corticosteroids); biologic agents targeting tumor necrosis factor-alpha (TNF-α) and the interleukin (IL)−12/23 pathways; immunosuppressive drugs that inhibit the Janus kinase (JAK) pathway; and antibiotics [14–16]. The gene discussed is TNF; the disease is inflammatory bowel disease.